Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Leuven, Belgien, 3000
- UZ Leuven
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute Clinical Research Unit
-
-
-
-
West Midlands
-
Sheffield, West Midlands, Det Forenede Kongerige, S102JF
- Royal Hallamshire Hospital
-
-
-
-
California
-
San Diego, California, Forenede Stater, 92103
- University of California San Diego Medical Center
-
San Francisco, California, Forenede Stater, 94115
- California Pacific Medical Center
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- University of South Florida
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- The Emory Clinic
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Charlestown, Massachusetts, Forenede Stater, 2129
- Massachusetts General Hospital, MA
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, EC037
- Penn State Milton S. Hershey Medical Center
-
-
-
-
Hérault
-
Montpellier, Hérault, Frankrig, 34295
- Hopital Gui de Chauliac, Service de Neurologie
-
-
Paris
-
Paris cedex 13, Paris, Frankrig, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
CX
-
Utrecht, CX, Holland, 3584
- UMC Utrecht
-
-
-
-
-
Dublin, Irland, Dublin 9
- Beaumont Hospital
-
-
-
-
-
St. Gallen, Schweiz, 9007
- Kantonsspital St. Gallen
-
-
-
-
-
Berlin, Tyskland, 13125
- Charité - Campus Virchow-Klinikum
-
Hannover, Tyskland, 30625
- Medizinische Hochschule Hannover
-
Jena, Tyskland, 07743
- Universitaetsklinikum Jena
-
Ulm, Tyskland, 89081
- Universitaetsklinikum Ulm
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Key Inclusion Criteria:
- A diagnosis of sporadic or familial ALS
- ALS onset within ≤5 years
- Must be 16 to 85 years of age, inclusive, for sites in the United States and 18 to 85 years of age, inclusive, for all sites outside of the United States
Key Exclusion Criteria:
- History of or positive test result at Screening for human immunodeficiency virus (HIV)
- History of or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (HBV)
- Possibility of neuromuscular weakness other than ALS
- Unspecified reasons that, in the opinion of the site Investigator, make the subject unsuitable for enrollment or unlikely to be able to complete, at a minimum, the Month 6 Visit
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured.
These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized.
Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
Optional, to be administered at each site's Investigator's discretion.
MUNE is used to estimate the number of functioning motor units.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
MUNIX estimates functioning motor units within a muscle.
CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
HHD tests isometric strength of multiple muscles using standard participant positioning.
Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
Vital capacity will be measured by means of an SVC test, administered in the upright position.
Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Tidsramme: Baseline to Month 6 and Baseline to Month 12
|
The ALSFRS-R has been demonstrated to predict survival.
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills.
There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.
|
Baseline to Month 6 and Baseline to Month 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Tidsramme: Baseline to Month 24
|
Baseline to Month 24
|
|
Comparison between 6-month changes for muscle electrophysiological measures
Tidsramme: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for muscle strength measures
Tidsramme: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for functional measures
Tidsramme: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison of molecular biomarkers with disease progression
Tidsramme: Baseline to Month 12
|
Baseline to Month 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 999AS003
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .